Dexcom shares plummet 30% after company lowers fiscal year guidance

Core Insights - Dexcom's shares fell over 34% in after-hours trading following disappointing Q2 revenue and weak guidance [1] - The company reported adjusted earnings per share of 43 cents, exceeding the expected 39 cents, but revenue of $1 billion fell short of the $1.04 billion forecast [1] - Revenue increased by 15% year-over-year from $871.3 million, with net income rising to $143.5 million from $115.9 million [1] Financial Performance - Q2 adjusted earnings per share: 43 cents vs. 39 cents expected [1] - Q2 revenue: $1 billion vs. $1.04 billion expected [1] - Year-over-year revenue growth: 15% from $871.3 million [1] - Net income for Q2: $143.5 million, up from $115.9 million [1] Future Guidance - Q3 revenue expectation: between $975 million to $1 billion [1] - Updated full fiscal year revenue guidance: between $4 billion and $4.05 billion, down from previous guidance of $4.20 billion to $4.35 billion [1] Strategic Initiatives - CEO Kevin Sayer acknowledged that execution did not meet high standards despite advancing key strategic initiatives [2] - The company sees a unique opportunity to serve more customers globally with its differentiated product portfolio [2] - Actions are being taken to improve execution and position the company for long-term growth [2]